Cel Sci (CVM) revenue and earnings history
Cel Sci's annual figures for 17 fiscal years, as filed with the SEC.
Over 3 years, from fiscal 2011 to fiscal 2014, revenue grew at a compound rate of −34.9% a year.
Revenue and net income, 17 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Sep 30, 2025 | — | −$24.8M | −$25.4M | −$17.1M | $38K | −$17.2M | $1.91M | — | — | $11M | $5.68M | 10-K |
| 2024ended Sep 30, 2024 | — |
The latest quarter, insider trades and fund moves: Cel Sci (CVM) on OQRO.
Common questions
How fast has Cel Sci's revenue grown?
From $956K in fiscal 2011 to $264K in fiscal 2014: a compound annual growth rate of −34.9% over 3 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Cel Sci been profitable?
It reported a net loss in 16 of the years shown (2009, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025). The highest net income was $10.5M in fiscal 2010.
What was Cel Sci's free cash flow in fiscal 2025?
−$17.2M: operating cash flow of −$17.1M minus capital expenditure of $38K. OQRO calculates free cash flow this way from the two filed lines.
Where these figures come from
The SEC’s companyfacts data: every figure Cel Sci tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.